Acurx Advances Ibezapolstat Toward Phase 3 Development
Staten Island, New York, August 17, 2026 Acurx Pharmaceuticals, Inc., a late-stage biopharmaceutical company developing antibiotics for difficult-to-treat bacterial...
CDI
Advertisement
Acurx Pharmaceuticals Advances Ibezapolstat Toward Phase 3
STATEN ISLAND, N.Y., August 14, 2026 Acurx Pharmaceuticals, Inc. reported its second-quarter 2026 financial results and provided a business...
Vedanta Biosciences Secures $60M to Advance Phase 3 VE303
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
Genprex and Roche Diagnostics Advance TROP2 Biomarker Strategy
Austin, Texas, August 3, 2026 Genprex, Inc. announced a collaboration with Roche Diagnostics to conduct biomarker assay validation studies...
Keenova Publishes New XIAFLEX Data in Peyronie’s Disease
Dublin, Ireland, August 3, 2026 Keenova Therapeutics plc announced the publication of a new manuscript evaluating XIAFLEX® (collagenase clostridium...
Advertisements
Acurx Gains FDA Guidance for Ibezapolstat Phase 3 Program
Staten Island, New York, August 3, 2026 Acurx Pharmaceuticals, Inc. announced further regulatory guidance from the U.S. Food and...
Acurx Pharmaceuticals Showcases DNA pol IIIC Antibiotic Breakthrough
STATEN ISLAND, N.Y., June 16, 2026 Acurx Pharmaceuticals has announced the presentation of new scientific findings from its ongoing...
Vedanta Biosciences Advances VE303 Phase 3 Trial in CDI
CAMBRIDGE, Mass., April 2, 2026 Vedanta Biosciences announced that its pivotal Phase 3 RESTORATiVE303 clinical trial of VE303 will...
Advertisement
